Esperion Therapeutics Inc.
3891 Ranchero Drive
Suite 150
Ann Arbor
Michigan
48108
United States
200 articles with Esperion Therapeutics Inc.
-
For Daiichi Sankyo, recent results from the Phase III CLEAR trial of Esperion Therapeutics’ Nexletol (bempedoic acid) were not convincing enough to trigger a milestone payment.
-
With the results from the CLEAR outcomes study, Esperion is poised for a major inflection in sales and is targeting blockbuster status, said CEO Sheldon Koenig on an investor call Monday.
-
With the Thanksgiving season upon us, there are many reasons for biopharma and life sciences companies to say thanks, including for new leaders.
-
The 71st annual American College of Cardiology's Scientific Session saw several wins over the weekend, led by some of the life sciences industries' largest companies.
-
In addition to massive layoffs – around 60% of its workforce – Yumanity also said it is considering “strategic alternatives” to its financial woes, including the possibility of selling or merging.
-
Movers & Shakers, Jan. 7
1/7/2022
With the turn of the calendar, biopharma and life sciences organizations have bolstered their leadership teams and board with these Movers & Shakers. -
From the continuing fight against COVID-19 to new companies emerging in exciting therapeutic areas to the people who mattered most, here’s a look at just some of the biggest successes, most dramatic flops – and a few that fall somewhere in between.
-
It’s not unusual for biopharma companies to end the year with a restructuring that includes job cuts. Here are some of these companies.
-
Products getting regulatory approval and hitting the market doesn’t always spell success for companies, especially during a global pandemic. Michigan-based Esperion has learned that lesson all too well.
-
BioSpace Movers & Shakers, July 2
7/2/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Esperion and Otsuka Team Up for Cardiovascular Drug Development and Commercialization in Japan
4/21/2020
The collaboration for development and commercialization combines Esperion's knowledge in lipid management and Otsuka's extensive cardiovascular drug advancement and marketing in Japan. -
Nexlizet is expected to be on the market in the U.S. in July 2020.
-
The company is planning for its drug for cholesterol lowering medications to hit the streets by the end of March. It will provide a new option to all the patients.
-
The U.S. Food and Drug Administration has a busy week planned for drug review. Here’s a look at this week’s schedule.
-
Esperion to Present at the 38th Annual J.P. Morgan Healthcare Conference
1/7/2020
Replay of the webcast will be archived on the Company's website for 90 days following the event.
-
Esperion Announces Publication in the Journal of the American Medical Association of Bempedoic Acid Phase 3 Study 2 Results
11/12/2019
Study 2 Demonstrated that Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP
-
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter Financial Results
11/6/2019
Esperion provided bempedoic acid franchise development program updates and financial results for the third quarter ended September 30, 2019.
-
Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of Bempedoic Acid to be Presented at the American Heart Association 2019 Scientific Sessions
11/4/2019
Esperion announced that pooled analyses from four Phase 3 clinical trials of bempedoic acid will be presented at the American Heart Association Scientific Sessions in Philadelphia on Sunday, November 17, 2019.
-
Esperion to Report Third Quarter 2019 Financial Results November 6, 2019
10/29/2019
Esperion announced it will report third quarter 2019 financial results on November 6, 2019 before U.S. financial markets open..
-
Bempedoic Acid Included in Top 10 Medical Innovations for 2020 List
10/25/2019
Esperion announced that bempedoic acid was included in the “Top 10 Medical Innovations for 2020” at Cleveland Clinic’s 2019 Medical Innovation Summit on Wednesday, October 23rd.